# US 2003/0216442 A1 · Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216442 A1
- Document ID: US20030216442A1
- Status: Published application
- Kind: A1
- Application number: 10/408,877
- Filed: 2003-04-08
- Published: 2003-11-20
- Earliest claimed: 2002-04-10
- Assignees: Wyeth
- Inventors: Joseph P. Sabatucci; Craig E. Caufield; Alexander A. Greenfield; Schuyler Antane; Eamonn P. Morrison
- Web page: https://patentgrep.com/patent/US20030216442A1

## CPC

- C07D 213/30: Oxygen atoms
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 277/24: Radicals substituted by oxygen atoms
- C07D 277/64: with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention provides compounds of formula I, having the structure 1 wherein R1, R4, A, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof, that are useful in treating metabolic disorders mediated by insulin resistance or hyperglycemia.

## Claims

### Claim 1

A compound of formula (I) having the structure
14
wherein:
Z is
15
Y is selected from O, S, N, C═C, or C═N;
R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh; or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—; or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
R4 is hydrogen or halogen, A is a bond; or
16
wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms; R8 is hydrogen or alkyl of 1-6 carbon atoms;
or a pharmaceutically acceptable salt form thereof.

### Claim 2 (depends on 1)

The compound of claim 1, having the structure of formula (II)
17
wherein,
A is
18
Y is —C═C—;
or a pharmaceutically acceptable salt form thereof.

### Claim 3 (depends on 1)

The compound of claim 1, having the structure of formula (III):
19
or a pharmaceutically acceptable salt form thereof.

### Claim 4 (depends on 1)

The compound of claim 1, having the structures of formulae (IV) and (V):
20
wherein:
R1 is selected from SO2CF3, SO2Ar, SO2CH3, SO2CH2CF3, CONH2, CSNHCH3, CONHAr, COAr, or COCCl3;
Ar represent an optionally mono- or di-substituted phenyl, naphthyl, pyridyl, or quinolyl group; and
R2 and R3 are independently selected from the group of H, Cl, Br, F, OCH3, CF3, CN, or CH3; or a pharmaceutically acceptable salt form thereof.

### Claim 5 (depends on 1)

The compound of claim 1, having the structures of formulae (VI) and (VII):
21
wherein:
22
represents a group selected from:
23
or a pharmaceutically acceptable salt form thereof.

### Claim 6 (depends on 1)

The compound of claim 1, having the structure of formula (VII):
24
or a pharmaceutically acceptable salt form thereof.

### Claim 7 (depends on 1)

The compound of claim 1, which is
a) C,C,C-Trifluoro-N-[5-biphenyl-3-ylmethoxy)-naphthalen-2-yl]-methanesulfonamide;
b) N-[5-(3′,4′-Dichloro-3-fluoro-biphenyl-4-ylmethoxy)-naphthalen-2-yl]-C,C,C-trifluoro-methanesulfonamide;
c) N-[5-(4-naphthalen-2-yl-benzyloxy-3-ylmethoxy)-naphthalen-2-yl]-C,C,C-trifluoro-methanesulfonamide;
d) C,C,C-Trifluoro-N-[5-(3-fluoro-4′-trifluoromethyl-biphenyl-4-ylmethoxy)-naphthalen-2-yl]-methanesulfonamide;
e) N-[5-(4′-tert-Butyl-3-fluoro-biphenyl-4-ylmethoxy)-naphthalen-2-yl]-C,C,C-trifluoro-methanesulfonamide;
f) N-[5-(3,4′-Dichloro-biphenyl-4-ylmethoxy)-naphthalen-2-yl]-C,C,C-trifluoro-methanesulfonamide;
g) C,C,C-Trifluoro-N-[5-(3,3′,4′-trichloro-biphenyl-4-ylmethoxy)-naphthalen-2-yl]-methanesulfonamide;
h) N-{5-[2-(2,4-Difluoro-phenyl)-thiazol-4-ylmethoxy]-naphthalen-2-yl}-C,C,C-trifluoro-methanesulfonamide;
i) C,C,C-Trifluoro-N-{5-[2-(5-trifluoromethyl-pyridin-2-yl)-thiazol-4-yl-methoxy]naphthalen-2-yl}-methanesulfonamide;
j) C,C,C-Trifluoro-N-{5-[2-(4-methoxy-phenyl)-thiazol-4-ylmethoxy]-naphthalen-2-yl}-methanesulfonamide;
k) N-{5-[2-(4-trufluoromethyl-phenyl)-thiazol-4-ylmethoxy]-naphthalen-2-yl}-C,C,C-trifluoro-methanesulfonamide;
l) C,C,C-Trifluoro-N-[5-(3-fluoro-biphenyl-4-ylmethoxy)-naphthalen-2-yl]-methanesulfonamide; or
m) N-{5-[5-methyl-2-(4-trifluoromethylphenyl)-oxazol-4-ylmethoxy]naphthalen-2-yl}C,C,C-trifluoromethanesulfonamide
or a pharmaceutically acceptable salt thereof.

### Claim 8

A method of treating metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal in need thereof which comprises providing to said mammal, a compound of formula (I) having the structure
25
wherein:
Z is
26
Y is selected from O, S, N, C═C, or C═N;
R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh; or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—; or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
R4 is hydrogen or halogen,
A is a bond; or
27
wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
R8 is hydrogen or alkyl of 1-6 carbon atoms;
or a pharmaceutically acceptable salt form thereof.

### Claim 9

A method of modulating glucose levels in a mammal in need thereof which comprises providing to said mammal, a compound of formula (I) having the structure
28
wherein:
Z is
29
Y is selected from O, S, N, C═C, or C═N;
R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh; or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—; or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
R4 is hydrogen or halogen,
A is a bond; or
30
wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
R8 is hydrogen or alkyl of 1-6 carbon atoms;
or a pharmaceutically acceptable salt form thereof.

### Claim 10

A method of treating or inhibiting type 11 diabetes in a mammal in need thereof which comprises providing to said mammal, a compound of formula (I) having the structure
31
wherein:
Z is
32
Y is selected from O, S, N, C═C, or C═N;
R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh; or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—; or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
R4 is hydrogen or halogen,
A is a bond; or
33
wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
R8 is hydrogen or alkyl of 1-6 carbon atoms;
or a pharmaceutically acceptable salt form thereof.

### Claim 11

A method of treating primary hypertension in a mammal in need thereof, which comprises providing to said mammal a compound of formula (I) having the structure
34
wherein:
Z is
35
Y is selected from O, S, N, C═C, or C═N;
R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh; or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—; or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
R4 is hydrogen or halogen,
A is a bond; or
36
wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
R8 is hydrogen or alkyl of 1-6 carbon atoms;
or a pharmaceutically acceptable salt form thereof.

### Claim 12

A method of treating atherosclerosis in a mammal in need thereof, which comprises providing to said mammal a compound of formula (I) having the structure
37
wherein:
Z is
38
Y is selected from O, S, N, C═C, or C═N;
R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh; or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—; or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
R4 is hydrogen or halogen,
A is a bond; or
39
wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
R8 is hydrogen or alkyl of 1-6 carbon atoms;
or a pharmaceutically acceptable salt form thereof.

### Claim 13

A phramaceutical composition which comprises a compound of formula (I) having the structure
40
wherein:
Z is
41
Y is selected from O, S, N, C═C, or C═N;
R1 is selected from —SO2CF3, —SO2Ar, —SO2CH3, —SO2CH2CF3, —CONH2, —CSNHCH3, —CONHAr, —COAr, —COCCl3;
Ar is phenyl, naphthyl, pyridyl, or quinolyl, which may be optionally mono- or di-substituted with alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, halogen, hydroxyl, alkoxy of 1-6 carbon atoms, —CN, —NO2, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 1-6 carbon atoms per alkyl group, thio, alkylthio of 1-6 carbon atoms, alkylsulfinyl of 1-6 carbon atoms, alkylsulfonyl of 1-6 carbon atoms, alkoxycarbonyl of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, or benzoyl;
R2 and R3 are independently selected from hydrogen, halogen, hydroxy, -alkoxy of 1-6 carbon atoms, —CF3, —CN, alkyl of 1-6 carbon atoms, or —CH═CHPh; or R2 and R3 may be taken together as —C(CH3)2CH2CH2—C(CH3)2—, or —OCH2CH2O—; or R2 and R3 may be taken together as —CH═CH—CH═CH—, when A is not a bond;
R4 is hydrogen or halogen,
A is a bond; or
42
wherein R6, and R7 are each, independently, hydrogen, hydroxy, alkoxy of 1-6 carbon atoms, CF3, CN, or alkyl of 1-6 carbon atoms;
R8 is hydrogen or alkyl of 1-6 carbon atoms;
or a pharmaceutically acceptable salt form thereof, and a pharmaceutical carrier.
